Difference between revisions of "Trabectedin (Yondelis)"
m |
m |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Binds to the minor groove of DNA, which distorts the DNA helix and its major groove. This binding interrupts normal cell function and interferes with the expression of several several transcription factors, DNA binding proteins, and DNA repair mechanisms, which interrupts cell cycle and leads to tumor death.<ref name="insert">[http://www.janssen.ca/subcategory_docdownload?id=633 Trabectedin (Yondelis) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/trabectedin.pdf Trabectedin (Yondelis) package insert (locally hosted backup)]</ref> | Class/mechanism: Binds to the minor groove of DNA, which distorts the DNA helix and its major groove. This binding interrupts normal cell function and interferes with the expression of several several transcription factors, DNA binding proteins, and DNA repair mechanisms, which interrupts cell cycle and leads to tumor death.<ref name="insert">[http://www.janssen.ca/subcategory_docdownload?id=633 Trabectedin (Yondelis) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/trabectedin.pdf Trabectedin (Yondelis) package insert (locally hosted backup)]</ref> | ||
| Line 15: | Line 13: | ||
* 9/30/2004: Granted orphan status for treatment of [[Sarcoma | soft tissue sarcoma]]. | * 9/30/2004: Granted orphan status for treatment of [[Sarcoma | soft tissue sarcoma]]. | ||
* 3/29/2005: Granted orphan status for treatment of patients with [[Ovarian cancer | ovarian cancer]]. | * 3/29/2005: Granted orphan status for treatment of patients with [[Ovarian cancer | ovarian cancer]]. | ||
| + | * 10/23/2015: FDA approved "for the treatment of patients with unresectable or metastatic [[Sarcoma|liposarcoma or leiomyosarcoma]] who have received a prior [[:Category:Anthracyclines|anthracycline-]]containing regimen" | ||
| + | |||
| + | ==Also known as== | ||
| + | ecteinascidin 743 or ET-743 | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 13:56, 25 October 2015
General information
Class/mechanism: Binds to the minor groove of DNA, which distorts the DNA helix and its major groove. This binding interrupts normal cell function and interferes with the expression of several several transcription factors, DNA binding proteins, and DNA repair mechanisms, which interrupts cell cycle and leads to tumor death.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Trabectedin (Yondelis) patient drug information from manufacturer[3]
- Trabectedin (Yondelis) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 9/30/2004: Granted orphan status for treatment of soft tissue sarcoma.
- 3/29/2005: Granted orphan status for treatment of patients with ovarian cancer.
- 10/23/2015: FDA approved "for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have received a prior anthracycline-containing regimen"
Also known as
ecteinascidin 743 or ET-743